Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > paroxysmal nocturnal hemoglobinuria treatment market
Get a free sample of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market positions. These efforts are aimed at enhancing their product and service offerings, expanding their geographic reach, and investing in advanced technologies. The market also witnesses the entry of new players, further intensifying the competitive landscape.
The company profile section includes both companies that have commercially available drugs in the market as well as those in the clinical phase of development. Prominent players operating in the market include:
The complement inhibitors segment in the market generated USD 1.4 billion in 2023 owing to the strong clinical results.
North America paroxysmal nocturnal hemoglobinuria treatment market held 46.6% in 2023 favored by the need for insurance coverage for high-cost drugs.
The paroxysmal nocturnal hemoglobinuria treatment market was valued at USD 3.9 billion in 2023 and is expected to grow at 11.2% CAGR during 2024-2032 due to the rising prevalence of PNH.
Amgen Inc., Apellis Pharmaceuticals, Inc., AstraZeneca Plc, Children's National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc., and Teva Pharmaceuticals Industries Ltd. among others.